Amgen reported strong Q2 2016 results, with revenues up 6% and adjusted EPS up 11% year-over-year. The company raised its full-year guidance, reflecting confidence in its growth products and upcoming clinical milestones, such as the Repatha outcomes study. Management's optimistic tone and solid execution suggest a positive short-term impact on the stock price.

[1]